M. Takahashi

Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.

H. Rugo, H. Iwata, D. Juric, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial.

H. Rugo, H. Iwata, D. Juric, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial.

H. Iwata, K. Yonemori, N. Masuda, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib

S. Ramaswamy, E. Edelman, S. Maheswaran, 2011, Oncogene.

135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

C. Denkert, H. McArthur, S. Kuemmel, 2022, Annals of Oncology.

Superiority of Radioisotope over Blue Dye for Sentinel Lymph Node Detection in Breast Cancer

T. Hibi, M. Kitajima, Y. Kitagawa, 2010, European Surgical Research.

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

P. Fasching, L. Pusztai, C. Denkert, 2019, Annals of Oncology.

Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: A real-world prospective study.

H. Mukai, K. Inoue, J. Tsurutani, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.